| |
| |
|
| Insider
Information: |
Cadavid Diego |
| Relationship: |
Chief Medical Officer |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
169,821 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$113,477 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
169,821 |
|
|
| Total
Value |
$113,477 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Fulcrum Therapeutics, Inc. |
FULC |
SVP Clinical Development |
2020-07-01 |
65,714 |
|
0 |
Premium* |
|
|
X4 Pharmaceuticals Inc |
XFOR |
Chief Medical Officer |
2022-03-01 |
104,107 |
2021-03-24 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XFOR |
X4 Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
97,000 |
104,107 |
0 |
- |
|
| XFOR |
X4 Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2022-02-11 |
4 |
AS |
$0.00 |
$0 |
D/D |
(928) |
7,107 |
0 |
% |
|
| XFOR |
X4 Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
8,035 |
8,035 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-07-01 |
4 |
AS |
$18.30 |
$19,599 |
D/D |
(1,071) |
65,714 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-25 |
4 |
AS |
$22.00 |
$32,098 |
D/D |
(1,459) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-25 |
4 |
OE |
$4.83 |
$7,047 |
D/D |
1,459 |
68,244 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-10 |
4 |
OE |
$4.83 |
$1,937 |
D/D |
401 |
67,186 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-10 |
4 |
AS |
$22.00 |
$8,822 |
D/D |
(401) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-05 |
4 |
AS |
$20.18 |
$9,101 |
D/D |
(451) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-05 |
4 |
OE |
$4.83 |
$2,178 |
D/D |
451 |
67,236 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-04 |
4 |
AS |
$20.05 |
$4,531 |
D/D |
(226) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-04 |
4 |
OE |
$4.83 |
$1,092 |
D/D |
226 |
67,011 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-03 |
4 |
AS |
$20.18 |
$6,820 |
D/D |
(338) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-03 |
4 |
OE |
$4.83 |
$1,633 |
D/D |
338 |
67,123 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-02 |
4 |
AS |
$20.00 |
$900 |
D/D |
(45) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-06-02 |
4 |
OE |
$4.83 |
$217 |
D/D |
45 |
66,830 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-05-29 |
4 |
AS |
$20.04 |
$4,007 |
D/D |
(200) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-05-29 |
4 |
OE |
$4.83 |
$966 |
D/D |
200 |
66,985 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-05-28 |
4 |
OE |
$4.83 |
$2,898 |
D/D |
600 |
67,385 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-05-28 |
4 |
AS |
$20.00 |
$12,000 |
D/D |
(600) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-05-12 |
4 |
AS |
$18.00 |
$33,480 |
D/D |
(1,860) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-05-12 |
4 |
OE |
$4.83 |
$8,984 |
D/D |
1,860 |
68,645 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-03-02 |
4 |
AS |
$17.26 |
$37,255 |
D/D |
(2,143) |
66,785 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
SVP Clinical Development |
• – – |
2020-02-03 |
4 |
AS |
$17.33 |
$37,142 |
D/D |
(2,143) |
68,928 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
See RemarksOfficer |
• – – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
71,071 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
